In the adjuvant setting, nivolumab or pembrolizumab should be offered to patients with resected stage IIIA/B/C/D BRAF wild-type cutaneous melanoma....For patients with resected stage IIIA/B/C/D disease that is BRAF wild type, the following options should be offered (in no particular order): nivolumab × 52 weeks OR pembrolizumab × 52 weeks....For patients with BRAF wild-type unresectable/metastatic cutaneous melanoma, the following treatment options should be offered (in no particular order): ipilimumab plus nivolumab followed by nivolumab OR nivolumab OR pembrolizumab...(Type: Evidence based, benefits outweigh harms; Evidence quality: High; Strength of recommendation: Strong).